Inhaled drug shows promise for lung transplant rejection in phase 3 trial

NCT ID NCT03656926

Completed Disease control Sponsor: Zambon SpA Source: ClinicalTrials.gov ↗

First seen Feb 11, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tested whether adding an inhaled form of cyclosporine A (L-CsA) to standard treatment helps people who have chronic lung rejection after a double lung transplant. The trial included 169 adults who had their transplant at least a year earlier. The main goal was to see if the drug could slow the decline in lung function over 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Banner Health

Phoenix, Arizona, 85013, United States
Baylor College of Medicine

Houston, Texas, 77030, United States
Baylor University Medical Center

Dallas, Texas, 75246, United States
CHU Erasme

Brussels, Belgium
CHU Hopital Nord

Marseille, France
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University Medical Center

New York, New York, 10032, United States
Complexo Hospitalario de A Coruna

A Coruña, Spain
Copenhagen University Hospital

Copenhagen, Denmark
Duke University Medical Center

Durham, North Carolina, 27110, United States
Hannover Medical School

Hanover, Germany
Hospital Marques de Valdecilla

Santander, Spain
Hospital Puerta de Hierro

Madrid, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Reina Sofía

Córdoba, 14004, Spain
Houston Methodist Hospital

Houston, Texas, 77030, United States
Hôpitaux Universitaires de Strasbourg

Strasbourg, France
Indiana University

Indianapolis, Indiana, 46202, United States
Johns Hopkins University Hospital

Baltimore, Maryland, 21287, United States
LMU Klinikum Großhadern

Munich, Germany
Marie-Lannelongue

Le Plessis-Robinson, 92350, France
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Medical University of Vienna

Vienna, Austria
Ohio State University Medical Center

Columbus, Ohio, 43210, United States
Rabin Medical Center

Petah Tikva, Israel
Royal Papworth Hospital

Cambridge, United Kingdom
Stanford University Hospital

Palo Alto, California, 94305, United States
Temple University Hospital

Philadelphia, Pennsylvania, 19140, United States
UC San Francisco

San Francisco, California, 94143, United States
UCLA Medical Center

Los Angeles, California, 90095, United States
Universitair Ziekenhuis Leuven

Leuven, 3000, Belgium
University Hospital LA Fe

Valencia, Spain
University of Florida Medical Center

Gainesville, Florida, 32608, United States
University of Kentucky Albert B. Chandler Hospital

Lexington, Kentucky, 40508, United States
University of Manchester

Manchester, United Kingdom
University of Maryland

Baltimore, Maryland, 21201, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of South Florida

Tampa, Florida, 33606, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

BRONCHIOLITIS OBLITERANS CHRONIC LUNG ALLOGRAFT DYSFUNCTION CHRONIC REJECTION OF LUNG TRANSPLANT LUNG TRANSPLANT FAILURE AND REJECTION LUNG TRANSPLANT FAILURE AND REJECTION LUNG TRANSPLANT REJECTION LUNG TRANSPLANT REJECTION LUNG TRANSPLANT; COMPLICATIONS LUNG TRANSPLANT; COMPLICATIONS